May 10, 2021 -- Novavax is highlighting positive preclinical results for a combination influenza/COVID-19 vaccine.
The vaccine is a combination of NanoFlu and the company's COVID-19 candidate NVX-CoV2373; results from the preclinical animal trial were published May 5 on bioRxiv. The study found that the combination elicited strong responses against both influenza A and B and protected against the SARS-CoV-2 virus, according to the firm. It expects to begin clinical studies of the combination by the end of this year.
NVX-CoV2373 is also being evaluated in two phase II trials, one in South Africa and one in the U.S. and Australia, as well as two phase III trials, one in the U.K. and another in the U.S. and Mexico, according to Novavax.
Copyright © 2021 scienceboard.net